



Russia: 10 pharma companies added to monopoly register

Law-Now Russia

04.05.2009

Ten international pharmaceutical manufacturers have been included in the register for companies with a dominant position in or control over at least 35% of a particular market.

The ten companies are the Russian branches of IHCC, Johnson & Johnson, Galen Pharma, Roche-Moscow, Novartis Pharma, BIOTECH, Nycomed Distribution Center, Schering AG, Astellas Pharma and Novo Nordisk.

Roche, Novartis, Bayer-Schering, Nycomed, Johnson & Johnson and Novo Nordisk were reported by market research group DSM as having only 17.8% of the total monetary value of the Russian pharmaceutical market in 2008.

The Federal Antimonopoly Service has analysed the Russian market for drugs to treat haemophilia, cystic fibrosis, hypophysial nanism, Gaucher's disease, myeloleukemia and multiple sclerosis, and those used after organ or tissue transplants. There are no Russian analogues for the drugs manufactured by these companies. It decided that the companies have a dominant position in this market.

By including these companies in the register, the Federal Antimonopoly Service is able to supervise their business activities to ensure there is no abuse of a dominant market position, by actions such as setting high or low prices, withdrawing products from circulation or limiting their supply, introducing exclusivity for distributors or refusing to use them and preventing competing products from entering the market.

Any monopoly abuse could lead to a company being fined between 1% and 15% of its turnover in the relevant market.

Law: Order No. 193 dated 3 April 2009 by the Federal Antimonopoly Service

For further information, please contact:

[Julia Fedorova](#)

Moscow

+7 495 786 40 38